Assessment Status | NCPE Assessment Process Complete |
HTA ID | 21066 |
Drug | Osimertinib |
Brand | Tagrisso® |
Indication | For adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. |
Assessment Process | |
Rapid review commissioned | 20/12/2021 |
Rapid review completed | 13/01/2022 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 31/01/2022 |
Pre-submission consultation with Applicant | 15/03/2022 |
Full submission received from Applicant | 16/08/2022 |
Preliminary review sent to Applicant | 27/01/2023 |
NCPE assessment re-commenced | 13/03/2023 |
Factual accuracy sent to Applicant | 03/05/2023 |
NCPE assessment re-commenced | 10/05/2023 |
NCPE assessment completed | 23/05/2023 |
NCPE assessment outcome | The NCPE recommends that osimertinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.